- Home
- EMF vs TVRD Comparison
EMF vs TVRD Comparison
Compare EMF & TVRD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EMF
- TVRD
- Stock Information
- Founded
- EMF 1987
- TVRD 2017
- Country
- EMF United States
- TVRD United States
- Employees
- EMF N/A
- TVRD N/A
- Industry
- EMF Finance/Investors Services
- TVRD Biotechnology: Pharmaceutical Preparations
- Sector
- EMF Finance
- TVRD Health Care
- Exchange
- EMF Nasdaq
- TVRD Nasdaq
- Market Cap
- EMF 254.5M
- TVRD 246.5M
- IPO Year
- EMF N/A
- TVRD N/A
- Fundamental
- Price
- EMF $17.72
- TVRD $4.49
- Analyst Decision
- EMF
- TVRD Buy
- Analyst Count
- EMF 0
- TVRD 7
- Target Price
- EMF N/A
- TVRD $51.67
- AVG Volume (30 Days)
- EMF 29.3K
- TVRD 716.6K
- Earning Date
- EMF 01-01-0001
- TVRD 11-21-2025
- Dividend Yield
- EMF 6.16%
- TVRD N/A
- EPS Growth
- EMF N/A
- TVRD N/A
- EPS
- EMF N/A
- TVRD N/A
- Revenue
- EMF N/A
- TVRD N/A
- Revenue This Year
- EMF N/A
- TVRD N/A
- Revenue Next Year
- EMF N/A
- TVRD N/A
- P/E Ratio
- EMF N/A
- TVRD N/A
- Revenue Growth
- EMF N/A
- TVRD N/A
- 52 Week Low
- EMF $10.58
- TVRD $4.48
- 52 Week High
- EMF $12.67
- TVRD $43.65
- Technical
- Relative Strength Index (RSI)
- EMF 65.21
- TVRD 19.60
- Support Level
- EMF $16.82
- TVRD $4.63
- Resistance Level
- EMF $18.01
- TVRD $5.00
- Average True Range (ATR)
- EMF 0.27
- TVRD 0.44
- MACD
- EMF 0.04
- TVRD 0.22
- Stochastic Oscillator
- EMF 77.39
- TVRD 2.83
About EMF Templeton Emerging Markets Fund
Templeton Emerging Markets Fund is a closed-end management investment company. It seeks long-term capital appreciation by investing, under normal market conditions, at least 80% of its net assets in emerging country equity securities. It invests in various sectors such as Pharmaceuticals, Beverages, Broadline Retail, Metals &Mining, Banks, Food Products, Semiconductors & Semiconductor Equipment, insurance, Entertainment, and others.
About TVRD Tvardi Therapeutics Inc. Common Stock
Tvardi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases. Its key product candidate, TTI-101, is in Phase 2 clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC). Its second product candidate, TTI-109, is structurally related to, yet chemically distinct from, TTI-101 and is designed to enhance the ability to target STAT3.